HK1155066A1 - Novel soluble cd83 polypeptides, formulations and methods of use - Google Patents

Novel soluble cd83 polypeptides, formulations and methods of use

Info

Publication number
HK1155066A1
HK1155066A1 HK11109074.7A HK11109074A HK1155066A1 HK 1155066 A1 HK1155066 A1 HK 1155066A1 HK 11109074 A HK11109074 A HK 11109074A HK 1155066 A1 HK1155066 A1 HK 1155066A1
Authority
HK
Hong Kong
Prior art keywords
polypeptides
formulations
methods
novel soluble
soluble
Prior art date
Application number
HK11109074.7A
Other languages
English (en)
Inventor
Stephen Brand
Chih-Hsiung Chou
Murray Moo-Young
Original Assignee
Argos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argos Therapeutics Inc filed Critical Argos Therapeutics Inc
Publication of HK1155066A1 publication Critical patent/HK1155066A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
HK11109074.7A 2008-05-23 2011-08-29 Novel soluble cd83 polypeptides, formulations and methods of use HK1155066A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12870908P 2008-05-23 2008-05-23
PCT/US2009/003174 WO2009142759A1 (en) 2008-05-23 2009-05-22 Novel soluble cd83 polypeptides, formulations and methods of use

Publications (1)

Publication Number Publication Date
HK1155066A1 true HK1155066A1 (en) 2012-05-11

Family

ID=41340432

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11109074.7A HK1155066A1 (en) 2008-05-23 2011-08-29 Novel soluble cd83 polypeptides, formulations and methods of use

Country Status (13)

Country Link
US (1) US20110182903A1 (ko)
EP (1) EP2288387B1 (ko)
JP (1) JP2011520959A (ko)
KR (2) KR101679084B1 (ko)
CN (1) CN102036690B (ko)
AU (1) AU2009249540B9 (ko)
BR (1) BRPI0913577B1 (ko)
CA (1) CA2725198A1 (ko)
HK (1) HK1155066A1 (ko)
IL (1) IL209207A (ko)
MX (1) MX2010012576A (ko)
RU (1) RU2535340C2 (ko)
WO (1) WO2009142759A1 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1422241A1 (en) 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US7169898B2 (en) 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
CN103243119B (zh) * 2013-05-20 2016-03-30 中国科学技术大学 可溶性cd83的表达和制备方法
US20190315878A1 (en) 2016-11-07 2019-10-17 Argos Therapeutics Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
CN110475571B (zh) * 2017-04-01 2023-04-04 Avm生物技术有限责任公司 细胞免疫疗法前细胞毒性预调理的替代
KR102282341B1 (ko) 2018-09-12 2021-07-27 아주대학교산학협력단 Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물
EP3895723A1 (en) * 2020-04-16 2021-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Scd83 for wound healing, hair growth, and skin and hair care

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5710262A (en) * 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
US5316920A (en) * 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
AU744254B2 (en) * 1997-08-26 2002-02-21 Zymogenetics Inc. Adipocyte-specific protein homologs
DE60020727T2 (de) 1999-10-27 2006-05-04 Robert London Zhong Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
US20020014242A1 (en) * 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US20050032725A1 (en) * 2002-10-09 2005-02-10 Toerrx, Inc. Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use
EP1422241A1 (en) * 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
DK2051987T3 (en) * 2006-08-18 2015-01-05 Argos Therapeutics Inc USE OF CD83 IN COMBINATION THERAPY

Also Published As

Publication number Publication date
AU2009249540A1 (en) 2009-11-26
IL209207A (en) 2014-05-28
EP2288387A4 (en) 2011-04-27
MX2010012576A (es) 2011-04-05
AU2009249540A8 (en) 2011-01-20
RU2010152553A (ru) 2012-06-27
EP2288387A1 (en) 2011-03-02
CN102036690A (zh) 2011-04-27
WO2009142759A1 (en) 2009-11-26
JP2011520959A (ja) 2011-07-21
IL209207A0 (en) 2011-01-31
US20110182903A1 (en) 2011-07-28
CN102036690B (zh) 2013-11-06
BRPI0913577A2 (pt) 2020-08-18
AU2009249540B2 (en) 2014-07-03
KR101679084B1 (ko) 2016-11-24
KR20110018381A (ko) 2011-02-23
RU2535340C2 (ru) 2014-12-10
BRPI0913577B1 (pt) 2022-05-31
CA2725198A1 (en) 2009-11-26
EP2288387B1 (en) 2013-02-13
KR20160104101A (ko) 2016-09-02
AU2009249540B9 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
HK1194071A1 (en) Certain triazolopyrazines, compositions thereof and methods of use therefor
HK1155066A1 (en) Novel soluble cd83 polypeptides, formulations and methods of use
HK1139864A1 (en) Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
EP2437602A4 (en) OPHTHALMIC FORMULATIONS, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THEIR USE
EP2306823A4 (en) FORMULATIONS OF 5-FLUOROCYTOSINE AND ITS USES
EP2231665A4 (en) NEW COMPOSITIONS AND METHODS OF USE
IL208613A (en) Aztidine derivatives, methods of preparation, preparations containing them and their use
ZA201007129B (en) Limk2 inhibitors,compositions comprising them,and methods of their use
HRP20130585T1 (en) Alkylthiazol carbamate derivatives, preparation thereof and their use as faah inhibitors
EP2271750A4 (en) URICASE COMPOSITIONS AND METHODS OF USE
ZA201102518B (en) Modified release formulation and methods of use
HK1158632A1 (en) Derivatives of 2-oxo-alkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same 2--1--2-
GB201210536D0 (en) Composition, use and method of preparation thereof
EP2296675A4 (en) ECHINODERM EXTRACTS, MANUFACTURING METHODS AND ITS USES
EP2350212A4 (en) POLYAMINO-ACETONITRILES, PROCESSES FOR PREPARING THEM AND USE THEREOF
HK1136303A1 (en) Formulation and use of ergosta-7,22-dien-3-ol -722--3-
HK1144093A1 (en) Sophocarpine-series derivative, and preparation method and use thereof
EP2205550A4 (en) FLUORINATED OXY CARBOXYLIC ACIDS, DERIVATIVES, AND METHODS OF PREPARATION
SI2139485T1 (sl) Postopki dajanja tetrahidrobiopterina, povezani sestavki in postopki merjenja
AU2008905185A0 (en) Methods and compositions for preparing hormone-depleted surem
EP2396002A4 (en) (2.2.2) BICYCLIC DERIVATIVES AND METHOD OF ADMINISTRATION